High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era

Leuk Res. 2020 Jul:94:106371. doi: 10.1016/j.leukres.2020.106371. Epub 2020 May 19.

Abstract

The clinical behavior of FL patients is heterogeneous. The levels of sIL-2R have been correlated with tumor burden and outcome in FL. However, the impact of IL-6 and TNF-α in this disease is unclear. We studied 253 patients diagnosed with grade 1-3a FL between 2002 and 2018, with available information on serum levels of sIL-2R, IL-6, and TNF-α at diagnosis. Patients with cytokine levels above the cutoff had features of a higher tumor burden and higher-risk disease. Levels of any of the studied cytokines above the cutoff and a higher number of cytokines above the cutoff impacted on a shorter PFS and OS. TNF-α levels were an independent predictor of a poorer PFS. No differences were observed in the risk of histological transformation or second malignancies. The determination of cytokine levels in FL patients is feasible in clinical practice, and elevated levels are associated with a higher tumor burden and poorer survival.

Keywords: Chemoimmunotherapy; Cytokines; Follicular lymphoma; Response; Survival.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cost of Illness
  • Disease-Free Survival
  • Female
  • Humans
  • Interleukin-6 / blood*
  • Lymphoma, Follicular* / blood
  • Lymphoma, Follicular* / drug therapy
  • Lymphoma, Follicular* / mortality
  • Male
  • Middle Aged
  • Neoplasm Proteins / blood*
  • Receptors, Interleukin-2 / blood*
  • Rituximab / administration & dosage*
  • Survival Rate
  • Tumor Necrosis Factor-alpha / blood*

Substances

  • IL6 protein, human
  • Interleukin-6
  • Neoplasm Proteins
  • Receptors, Interleukin-2
  • Tumor Necrosis Factor-alpha
  • Rituximab